The InnoCare Pharma Limited (HKG:9969) Yearly Results Are Out And Analysts Have Published New Forecasts

Investors in InnoCare Pharma Limited (HKG:9969) had a good week, as its shares rose 7.5% to close at HK$13.11 following the release of its annual results. It was an okay report, and revenues came in at CN¥2.4b, approximately in line with analyst estimates leading up to the results announcement. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Following the recent earnings report, the consensus from eight analysts covering InnoCare Pharma is for revenues of CN¥2.16b in 2026. This implies a definite 8.9% decline in revenue compared to the last 12 months. Yet prior to the latest earnings, the analysts had been forecasting revenues of CN¥2.12b and losses of CN¥0.03 per share in 2026. The thing that stands out most is that, while there’s been a modest lift to revenue estimates, the consensus no longer provides an EPS estimate. This impliesthat revenue is more important following the latest results.

See our latest analysis for InnoCare Pharma

We’d also point out that thatthe analysts have made no major changes to their price target of HK$21.02. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on InnoCare Pharma, with the most bullish analyst valuing it at HK$27.69 and the most bearish at HK$17.18 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 8.9% by the end of 2026. This indicates a significant reduction from annual growth of 27% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 25% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining – InnoCare Pharma is expected to lag the wider industry.

The Bottom Line

The most important thing to take away is that the analysts upgraded their revenue estimates for next year. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

At least one of InnoCare Pharma’s eight analysts has provided estimates out to 2028, which can be seen for free on our platform here.

Even so, be aware that InnoCare Pharma is showing 1 warning sign in our investment analysis , you should know about…

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.